Cost-effectiveness analysis in pharmacogenomics

被引:2
作者
Payne, Katherine [1 ]
Shabaruddin, Fatiha H. [1 ]
机构
[1] Univ Manchester, Sch Community Based Med, Manchester M13 9PL, Lancs, England
关键词
cost-effectiveness analysis; critical appraisal; pharmacogenomics; INHIBITOR THERAPY; ECONOMIC EVIDENCE; UNCERTAINTY; TECHNOLOGY; CHALLENGES; GUIDELINES; OUTCOMES; ISSUES;
D O I
10.2217/PGS.10.45
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The existence of finite healthcare budgets drives the need to consider opportunity cost and demonstrate that pharmacogenomic interventions offer added value, in terms of the relative costs and benefits, compared with current practice. This is where the framework of cost-effectiveness analysis is useful. Existing systematic reviews of economic evaluations of genetic technologies have all highlighted the need to improve the quality of the economics evidence base. More recent cost-effectiveness analyses of pharmacogenomics are generally of higher quality. The future will see an increase in the number of published cost-effectiveness analyses. Critical appraisal of these analyses is necessary to ensure the evidence base is sufficiently robust to inform resource allocation decisions at local and national levels.
引用
收藏
页码:643 / 646
页数:4
相关论文
共 27 条
[1]  
[Anonymous], GUID METH TECHN APPR
[2]  
[Anonymous], NHS EC EV DAT HDB
[3]   Economic analyses of human genetics services: A systematic review [J].
Carlson, JJ ;
Henrikson, NB ;
Veenstra, DL ;
Ramsey, SD .
GENETICS IN MEDICINE, 2005, 7 (08) :519-523
[4]   The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer [J].
Carlson, Josh J. ;
Garrison, Louis P. ;
Ramsey, Scott D. ;
Veenstra, David L. .
VALUE IN HEALTH, 2009, 12 (01) :20-27
[5]   Exploring uncertainty in cost-effectiveness analysis [J].
Claxton, Karl .
PHARMACOECONOMICS, 2008, 26 (09) :781-798
[6]   Use of evidence in economic decision models: Practical issues and methodological challenges [J].
Cooper, N. J. ;
Sutton, A. J. ;
Ades, A. E. ;
Paisley, S. ;
Jones, D. R. .
HEALTH ECONOMICS, 2007, 16 (12) :1277-1286
[7]   Overview of the pharmacoeconomics of pharmacogenetics [J].
Dervieux, Thierry ;
Bala, Mohan V. .
PHARMACOGENOMICS, 2006, 7 (08) :1175-1184
[8]  
Drummond MF, 2005, Methods for The Economic Evaluation of Health Care Programmes
[9]  
Elliott R., 2005, ESSENTIALS EC EVALUA, V3rd
[10]   The role of cost-effectiveness analysis in the era of pharmacogenomics [J].
Flowers, CR ;
Veenstra, D .
PHARMACOECONOMICS, 2004, 22 (08) :481-493